426
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

, , , &
Pages 307-317 | Received 25 Nov 2013, Accepted 31 May 2014, Published online: 18 Aug 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Leszek Czupryniak, Shashank R Joshi, Jaideep A Gogtay & Meena Lopez. (2016) Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. Expert Opinion on Pharmacotherapy 17:11, pages 1463-1473.
Read now
Bobeck S. Modjtahedi, Namrata Bose, Thanos D. Papakostas, Lawrence Morse, Demetrios G. Vavvas & Amar U. Kishan. (2016) Lipids and Diabetic Retinopathy. Seminars in Ophthalmology 31:1-2, pages 10-18.
Read now

Articles from other publishers (16)

Sachiko Y Kataoka, Noemi Lois, Sumihiro Kawano, Yuki Kataoka, Kana Inoue & Norio Watanabe. (2023) Fenofibrate for diabetic retinopathy. Cochrane Database of Systematic Reviews 2023:6.
Crossref
Elana Meer, J. Clay Bavinger, Yinxi Yu & Brian L. VanderBeek. (2022) Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmology 140:5, pages 529.
Crossref
Vânia Mozetic, Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca & Rachel Riera. (2019) Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome 11:1.
Crossref
Vânia Mozetic, Letícia Leonel, Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca, Taís Guimarães, Patricia Logullo & Rachel Riera. (2019) Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklist. Trials 20:1.
Crossref
Sylvie Feldman-Billard. (2019) Quel bénéfice attendre des traitements hypolipémiants sur la rétinopathie diabétique ?. Médecine des Maladies Métaboliques 13:4, pages 347-353.
Crossref
Rui Shi, Lei Zhao & Yun Qi. (2018) The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study. BMC Ophthalmology 18:1.
Crossref
Srilakshmi Srinivasan, Prathibha Hande, Jyoti Shetty & Sindhu Murali. (2018) Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology 66:1, pages 98.
Crossref
Bettina Eva Mirgeler. 2018. Diabetes-Therapie – informiert entscheiden. Diabetes-Therapie – informiert entscheiden 79 82 .
Gavin S Tan, Ning Cheung, Rafael Simó, Gemmy C M Cheung & Tien Yin Wong. (2017) Diabetic macular oedema. The Lancet Diabetes & Endocrinology 5:2, pages 143-155.
Crossref
Tobias Jakob, Alain J Nordmann, Stefan Schandelmaier, Ignacio Ferreira-González & Matthias Briel. (2016) Fibrates for primary prevention of cardiovascular disease events. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Yan Gong, Zhuo Shao, Zhongjie Fu, Matthew L. Edin, Ye Sun, Raffael G. Liegl, Zhongxiao Wang, Chi-Hsiu Liu, Samuel B. Burnim, Steven S. Meng, Fred B. Lih, John Paul SanGiovanni, Darryl C. Zeldin, Ann Hellström & Lois E.H. Smith. (2016) Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine 13, pages 201-211.
Crossref
Focke Ziemssen & Hansjürgen T. Agostini. 2016. Anti-Angiogenic Therapy in Ophthalmology. Anti-Angiogenic Therapy in Ophthalmology 89 130 .
Ryan Lee, Tien Y. Wong & Charumathi Sabanayagam. (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision 2:1.
Crossref
Radha Das, Rebecca Kerr, Usha Chakravarthy & Ruth E. Hogg. (2015) Dyslipidemia and Diabetic Macular Edema. Ophthalmology 122:9, pages 1820-1827.
Crossref
Rafael Simó, Olga Simó-Servat & Cristina Hernández. (2015) Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. Current Diabetes Reports 15:5.
Crossref
Christopher Mathew, Anastasia Yunirakasiwi & Srinivasan Sanjay. (2015) Updates in the Management of Diabetic Macular Edema. Journal of Diabetes Research 2015, pages 1-8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.